Caroline Marie
Gallati‡
a,
Sina Katharina
Goetzfried‡
a,
Anna
Ortmeier
abc,
Jessica
Sagasser
a,
Klaus
Wurst
d,
Martin
Hermann
e,
Daniel
Baecker
ab,
Brigitte
Kircher
bc and
Ronald
Gust
*a
aDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria. E-mail: ronald.gust@uibk.ac.at
bTyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria
cImmunobiology and Stem Cell Laboratory, Department of Internal Medicine V (Hematology and Oncology), Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
dInstitute for General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria
eDepartment of Anesthesiology and Critical Care Medicine, Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
First published on 8th February 2021
A series of bis[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(I) complexes (2a–f) containing methyl, fluoro or methoxy substituents at various positions in the 4-aryl ring was synthesized and evaluated for their anti-cancer properties in A2780 (wild-type and Cisplatin-resistant) ovarian carcinoma as well as LAMA 84 (imatinib-sensitive and -resistant) and HL-60 leukemia cell lines. The bis-NHC gold(I) complexes were more active compared to their related mono-NHC gold(I) analogues and reduced proliferation and metabolic activity in a low micromolar range. With the exception of 2d (3-F), the compounds displayed higher potency than the established drugs Auranofin and Cisplatin. The lack of effects against non-cancerous lung fibroblast SV-80 cells indicated a high selectivity towards tumor cells. All tested complexes generated reactive oxygen species in A2780cis cells; however, the induction of apoptosis was very low. Furthermore, thioredoxin reductase is not the main target of these complexes, because its inhibition pattern did not correlate with their biological activity.
Considerable progress in the research on gold-based drugs has been made since the isolation of N-heterocyclic carbenes (NHCs) by Arduengo and colleagues.14 Bulky substituents at the N1 and N3 of the used 1,3-dihydro-2H-imdazol-2-ylidene were exploited to prevent dimerization.15 This discovery offered the possibility of synthesizing novel NHCs, which are suitable as ligands for coordination to metals.
The NHC–metal bond is regarded as more stable than those formed by phosphines.16–18 The high stability is achieved by three contributions, including the σ → d and π → d donation of the NHC to the metal as well as the d → π* metal to NHC back-donation.
NHC gold(I) complexes showed potential anti-tumor activity, whereby in most cases bis-NHC derivatives ([(NHC)2AuI]+) were more effective than their related mono-NHC analogues (e.g., (NHC)AuIX; X = Cl, Br, I, thiols).19–32 Many bis-NHC gold(I) complexes displayed a remarkable cytotoxicity in low micromolar or even nanomolar ranges (see e.g., ref. 33–36).
Thioredoxin reductase (TrxR) is discussed as a possible target for (NHC)AuIX complexes. Gold(I) complexes generally possess high affinity to Se- and S-containing proteins.31 Therefore, besides mono-NHC gold(I) complexes, their [(NHC)2AuI]+ derivatives act as strong TrxR inhibitors, too.18,37–42 However, also other modes of action are proposed for bis-NHC gold(I) species, e.g., interference with the mitochondrial permeability transition or the mitochondrial apoptotic pathway. After accumulation of [(NHC)2AuI]+ within the mitochondria, a selective induction of apoptosis occurs, mediated by a two-stage ligand exchange reaction with cysteine/selenocysteine.41,42 Furthermore, multimodal mechanisms of action such as alterations in the nucleolus on telomeres and actin stress fibers have been described.43,44
In a previous study, we reported on the synthesis and biological activity of bromido[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(I) complexes. The compounds inhibited the growth and proliferation of A2780/A2780cis and HL-60 cells in the micromolar range.45 However, in aqueous solutions a ligand scrambling reaction to the related [(NHC)2AuI]+ species was noticed.46 Because these degradation products might participate in the biological activity of (NHC)AuIBr complexes, we synthesized a series of bis[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(I) derivatives bearing methyl, fluoro or methoxy substituents at position 4 of the 4-aryl ring (Scheme 1) and evaluated their anti-cancer effects using ovarian carcinoma and leukemia cell lines. The influence of the substitution pattern of the 4-aryl residue was exemplarily studied on 4/3-fluoro and 4/2-methoxy derivatives, which were easily available using conventional synthesis approaches.
Two synthesis routes were applied to obtain the bis-NHC gold(I) complexes 2a–f (Scheme 1). The first one (Method A) followed the synthesis of (NHC)AuIX complexes, but using a 2-fold excess of the ligand.27 The coordination of the ligands 1a–c, e, f to gold(I) was achieved in a consecutive reaction with Ag2O and subsequent transmetalation with Me2SAuCl. The excess of ligand guaranteed the nearly quantitative formation of the bis-NHC gold(I) species 2a–c, e, f. To obtain the 3-F derivative 2d in satisfying yield, a second procedure (Method B) was performed, in which the (NHC)AuIBr complex 3d was reacted with the ligand 1d in the presence of K2CO3. The final complexes were purified by column chromatography (DCM/EtOAc (1/1)).
For the characterization of 2a–f, 1H NMR, 13C NMR and UV-Vis spectroscopy as well as electrospray ionisation mass spectrometry (ESI-MS) were employed.
Unfortunately, the chemical shift of the signals in the 1H NMR spectra of the bis-NHC gold(I) complexes (Fig. S1–S6, ESI†) did not differ from those of the mono-NHC gold(I) complexes.45 However, in the 13C NMR spectra, the signal of the C2 atom changed upon coordination of a second NHC from about 176 ppm ((NHC)AuIBr) to approximately 183 ppm (Fig. S7–S12, ESI†), indicating the formation of bis-NHC gold(I) compounds.
The UV-Vis spectra of the ligands altered as a consequence of coordination to gold(I), too (Fig. S13, ESI†). The free ligand 1e, for instance, showed in its spectrum (Fig. S13A, ESI†) an absorption at 233 nm, which was shifted in 3e to 226 nm. Strong absorptions at 254 nm (3e, Fig. S13B, ESI†) and 275 nm (2e, Fig. S13C, ESI†) characterized the (NHC)AuIBr and [(NHC)2AuI]+ complexes, respectively. The maxima at 226 nm and 233 nm can be assigned to the π→π* transition of the NHC ligand, while that at 254 nm and 276 nm correspond to the metal to ligand charge transfer.47
ESI-MS (Fig. S14–S19, ESI†) further confirmed the identity of the complexes.
HPLC (Fig. S20–S25, ESI†) documented a purity of >99%. (NHC)AuIBr species possessed retention times of tret = 5.80–6.02 min, if an RP18 column and an acetonitrile/water (0.1% TFA) eluent with a gradient from 70 to 90% acetonitrile was used. The corresponding [(NHC)2AuI]+ complexes were well separated with tret = 6.63–8.52 min.
The structure of the bis-NHC gold(I) complexes was closely investigated using the example of 2a. It was possible to solve its X-ray crystal structure. Selected data are summarized in Table 1 and Fig. 1 shows the molecular (ORTEP) plot. 2a is a linear complex with conversely arranged ligands. The distance between the respective carbene carbons and the gold(I) centre amounts to 2.03 Å, very similar to that of the related mono-NHC gold(I) complexes (e.g., 3f: 2.00 Å).45
Crystal system | Monoclinic |
Space group | C2/c (no. 15) |
Unit cell dimensions | a = 15.3982(3) Å, α = 90° |
b = 9.2903(3) Å, β = 94.218(2)° | |
c = 29.2782(8) Å, γ = 90° | |
Volume | 4177.02(19) Å3 |
Z | 4 |
Density (calculated) | 1.941 mg m−3 |
Absorption coefficient | 5.780 mm−1 |
F(000) | 2328 |
Crystal size | 0.070 × 0.050 × 0.030 mm3 |
Θ range for data collection | 2.562 to 24.996° |
Index ranges | −18 ≤ h ≤ 18, −11 ≤ k ≤ 11, −34 ≤ l ≤ 34 |
Reflections collected | 12![]() |
Independent reflections | 3624 [R(int) = 0.0640] |
Absorption correction | None |
Refinement method | Full-matrix least-squares on F2 |
Data/restraints/parameters | 3624/0/238 |
Goodness-of-fit on F2 | 1.021 |
Final R indices [I > 2σ(I)] | R 1 = 0.0358, wR2 = 0.0563 |
R indices (all data) | R 1 = 0.0695, wR2 = 0.0624 |
Largest diff. peak and hole | 0.689 and −0.569 e Å−3 |
As it has already been reported, the ligands displayed scarcely any anti-proliferative activity.45
Auranofin and/or Cisplatin were used in each experiment as references. Both compounds diminished the proliferation of A2780 cells at 1 μM to about 4%, but reduced the growth of A2780cis cells only to 50–60% (Fig. 2).
The complexes 2a–e were less active in Cisplatin-sensitive A2780 cells at 1 μM and even enhanced the proliferation at the lowest concentration tested (0.1 μM) in cases of 2a–c, e. In contrast, in A2780cis cells, all compounds, except for 2d, demonstrated high activity at 0.5 and 1 μM. These concentrations are about 10-fold lower than those of the respective (NHC)AuIBr species required to achieve the same effects. The complexes 2a and 2b almost blocked the proliferation of A2780cis cells at 1 μM. Even at 0.5 μM, 2b caused a reduction to <10%. The 4-OCH3-substituted complex 2e was marginally less active (1 μM: 16%; 0.5 μM: 33%). Weaker anti-proliferative effects were observed for the 4-F derivative 2c (1 μM: 29%; 0.5 μM: 51%).
The shift of the 4-F and 4-OCH3 substituents led to contrary results. The 3-F derivative 2d was entirely inactive at all concentrations used, whereas 2f (2-OCH3 derivative) represented the most active complex and inhibited the proliferation of A2780cis cells already at 0.5 μM to 0.29% (Fig. 2).
To test if the complexes were able to overcome also other drug resistances, their anti-proliferative effects were analyzed against chronic myeloid leukemia LAMA-84 cells, sensitive and resistant to the tyrosine kinase inhibitor imatinib mesylate (STI), a drug, which revolutionized the treatment of this disease.48
Auranofin was inactive on the LAMA-84 STI-resistant cell line and reduced the proliferation of STI-sensitive cells at 1 μM only to approximately 50% (Fig. 3).
In general, the bis-NHC gold(I) complexes were less effective in LAMA-84 cells in relation to A2780 cells. A strong inhibition of proliferation was caused only by 2b (4-CH3) at 1 μM (LAMA-84 STI-sensitive: 10%; LAMA-84 STI-resistant: 25%). The positive results of 2f, as discussed above, were not confirmed on these cell lines (proliferation at 1 μM, LAMA-84 STI-sensitive: 27%; LAMA-84 STI-resistant: 58%). Therefore, it can be assumed that the circumvention of resistance in A2780 cells with 2a–f followed a specific mode of action, which has to be elucidated further.
The activity of the bis-NHC gold(I) complexes was also analyzed in HL-60 cells (Fig. 4). Auranofin did not influence these cells at concentrations ≤1 μM. In contrast, 2a–c reduced the proliferation at 0.1 μM to about 52–66%. The 2-OCH3-substituted complex 2f was again the most active one at 0.5 and 1 μM (inhibition to 8% and 2%, respectively). Its 4-OCH3 derivative 2e interfered with the proliferation only at 1 μM (proliferation: 34%).
For a better evaluation of the anti-proliferative effects, IC50 values were calculated on the basis of the data presented in Fig. 2–4. From Table 2 it can be deduced that especially the Cisplatin-resistant A2780cis cell line and HL-60 cells were highly sensitive to the complexes. Based on the above-mentioned results, the following descending order of effectiveness can be obtained for the 4-substituted derivatives: 2b (4-CH3) > 2a (H) > 2e (4-OCH3) > 2c (4-F). The complexes were active with IC50 values <1 μM. Interestingly, the shift of the 4-OCH3 substituent (2e) to position 2 (2f) further increased the activity, while the change of the fluorine substituent (4-F → 3-F) strongly suppressed the anti-proliferative capacity. The 3-F-substituted complex 2d reduced the proliferation only at concentrations >1 μM. This finding contradicts that of the related (NHC)AuIBr complexes. The mono-NHC gold(I) complexes were only effective at concentrations >5 μM and the substituents enhanced the efficacy in the order 4-OCH3 > 4-F > 4-CH3 > H. The shift of the substituents in the 3/2 position of the 4-aryl ring led in each case to an increase of potency.45
Compound | A2780 | A2780cis | LAMA-84 STI-sensitive | LAMA-84 STI-resistant | HL-60 |
---|---|---|---|---|---|
2a | 0.93 | 0.53 | 0.67 | >1 | 0.21 |
2b | 0.65 | 0.16 | 0.55 | 0.73 | 0.12 |
2c | >1 | 0.51 | 0.98 | >1 | 0.21 |
2d | >1 | >1 | >1 | >1 | >1 |
2e | 0.53 | 0.26 | 0.63 | >1 | 0.58 |
2f | 0.19 | 0.21 | 0.44 | 0.98 | 0.23 |
In a recently published study, the stability of the 4-OCH3-substituted (NHC)AuIBr complex 3e was investigated. The complex partially degraded in aqueous acetonitrile/water mixtures within 72 h to the [(NHC)2AuI]+ complex 2e and its gold(III) derivative [(NHC)2AuIIIBr2]+.46 It was postulated that this reaction also occurs under cell-culture conditions and that 2e is involved in the anti-proliferative capacity. Indeed, 2e was >10-fold more effective than 3e and might contribute to the effects of 3e. In contrast, 2a was one of the most potent bis-NHC gold(I) complexes in this study, while its mono-NHC derivative was completely inactive up to a concentration of 10 μM. These discrepancies require a more detailed assessment of the stability of (NHC)AuIX (X = Cl, Br, I) complexes under physiological conditions. Furthermore, it is necessary to know more about the effectiveness of [(NHC)2AuI]+ complexes in the presence of biomolecules. These studies are currently ongoing and will be part of forthcoming papers.
The complexes 2a, 2b, 2d and 2f were selected for investigations on the SV-80 lung fibroblast cell line to analyze the influence on the growth of non-cancerous cells (Fig. 5).
Among the complexes, only 2a and Auranofin reduced at 1 μM the proliferation of SV-80 cells to 6% and 77%, respectively. The other complexes did not affect the cell growth, indicating high tumor selectivity, as demonstrated in the examples of ovarian cancer and leukemic cell lines (especially HL-60).
The effects on the metabolic activity were slightly weaker than those on the proliferation (Fig. 6 and S26–S27, ESI†), but show the same trend in all cell lines. Therefore, only the effects on A2780 and A2780cis cells are discussed below.
Auranofin was nearly inactive at a concentration of 1 μM, while Cisplatin inhibited the metabolic activity of A2780 cells to 55% (Fig. 6). In general, and in agreement with the proliferation data, all compounds stimulated at 0.1 μM the metabolic activity. As the most potent complex, 2f reduced at 0.5 and 1 μM the viability of wild-type and resistant cells to about 10% and 20%, respectively. Compounds 2a–c were slightly less effective, but indicated at 1 μM a better response of resistant cells (metabolic activity of A2780cis cells: <20%; A2780 cells: 25–50%). The 4-OCH3 derivative 2e caused lower effects than 2b (4-CH3) and 2c (4-F). Besides the proliferation, the 3-F isomer 2d also stimulated the metabolic activity of the cells (e.g., about 140% (A2780) and 190% (A2780cis) at 0.5 and 1 μM).
In this assay, too, the bis-NHC gold(I) complexes were more effective than their (NHC)AuIBr analogues. The latter influenced the metabolic activity only at concentrations >7.5 μM. The exception was the 4-OCH3-substituted complex 3e, which reduced the viability of A2780cis cells at 5 μM to 15%.45
It is worth mentioning that the metabolic activity of the non-cancerous lung fibroblast cell line SV-80 was not diminished by the compounds (Fig. S28, ESI†), which again confirmed their selectivity towards tumor cells.
As gold(I) complexes can strongly affect the mROS content, the produced ROS in A2780cis cells were stained with MitoTrackerRed and analyzed with a confocal microscope according to a published procedure.51
All tested compounds (1 μM) induced the generation of mROS after 24 h (Fig. 8). Although quantification is not feasible, the obtained images indicate that 2c promoted the strongest oxidative stress. Only minimal production of mROS was observed upon incubation with 2b and Auranofin. Therefore, generation of ROS may be a general, not a specific, mode of action for these compounds.
![]() | ||
Fig. 8 Formation of mROS in A2780cis cells after incubation for 24 h with the complexes 2a–c, e (1 μM). A negative control of untreated A2780cis cells and Auranofin served as references. |
Interestingly, the inhibition of TrxR by the complexes did not correspond to their anti-proliferative/anti-metabolic activity. The nearly inactive 2d (3-F) and the most cytotoxic 2f (2-OCH3) complexes revealed to be the most potent inhibitors of TrxR. Both compounds completely repressed the conversion of DTNB (Fig. 9). The complexes 2a (H) and 2e (4-OCH3) exhibited similar activity as Auranofin, while 2b (4-CH3) and 2c (4-F) showed the weakest inhibition of TrxR.
The effects of 2c and 2e can be compared with that of their related (NHC)AuIBr analogues, both tested previously with the same assay set-up.452c and 2e showed a clearly lower potential to inhibit TrxR activity than related mono-NHC gold(I) complexes, which fully inactivated the enzyme. This finding can be attributed to the easier and faster substitution of the bromide ligand for selenium. This hypothesis, however, needs to be confirmed by reactivity studies, which are currently in progress in a further structure–activity relationship (SAR) study.
Based on these data, it appears that inhibiting TrxR is not the main mechanism of the anti-cancer action caused by the present bis-NHC gold(I) complexes.
The highest effects of the complexes were observed on the HL-60 cell line (Table 2) as they diminished the proliferation to approximately the half already at a concentration of 0.1 μM. It should be highlighted that the complexes 2a–c, e did not influence non-cancerous lung fibroblast SV-80 cells at concentrations <1 μM, indicating selectivity towards tumor cells.
All compounds induced the generation of ROS, although to a varying degree, which did not correlate with the cell growth inhibitory effects. The impact on the activity of TrxR was investigated, too, as this enzyme is generally assumed to be the main target of anti-tumor active gold complexes. Indeed, 2d and 2f completely terminated the conversion mediated by the enzyme, while 2a and 2e displayed similar activity as Auranofin. 2b and 2c showed only marginal inhibition of TrxR. An accordance with their anti-proliferative/anti-metabolic potency is not given.
This SAR study clearly demonstrated that the biological effects of the bis-NHC gold(I) complexes depended on the substitution pattern of the 4-aryl ring. However, an evident correlation between the modality of substitution and the activity cannot be deduced. At this point, a clear statement about the role of the substituent cannot be given. However, it was found that the shift of the electron-donating OCH3 group from the 4- to the 2-position improved the efficiency of the compound. The ligand scrambling reaction has to be taken into account, as the bis-NHC gold(I) complexes displayed a different anti-cancer pattern from those of the respective mono-NHC gold(I) complexes. Therefore, additional intrinsic and extrinsic factors, e.g., substituent effects, incubation temperature and solvents, have to be examined to gain more insight into the efficacy of [(NHC)AuI]+ complexes.
1H NMR (400 MHz, CDCl3): δ = 0.90 (t, 6 H, J = 7.4 Hz), 1.39 (t, 6 H, J = 7.4 Hz), 1.82 (qt, 4 H, J = 7.4, 7.4 Hz), 3.92 (s, 6 H), 4.12–4.31 (m, 8 H), 6.77 (d, 2 H, J = 8.8 Hz), 7.23–7.29 (m, 4 H), 7.38–7.41 (m, 6 H), 7.52 (dd, 2 H, J = 8.8, 2.4 Hz), 8.02 (d, 2 H, J = 2.0 Hz). 13C NMR (100 MHz, CDCl3): δ = 11.3, 17.4, 25.3, 44.5, 50.8, 53.8, 111.5, 116.8, 127.2, 128.9, 129.1, 129.7, 130.7, 132.8, 140.7, 148.6, 164.6, 183.3. ESI-MS m/z: 839.3310 (M − Br)+, calculated: 839.3349.
1H NMR (400 MHz, CDCl3): δ = 0.89 (t, 6 H, J = 7.4 Hz), 1.38 (t, 6 H, J = 7.2 Hz), 1.81 (qt, 4 H, J = 7.4, 7.4 Hz), 3.81 (s, 3 H), 3.93 (s, 3 H), 4.10–4.28 (m, 4 H), 6.77 (dd, 1 H, J = 8.6, 0.6 Hz), 6.90 (d, 2 H, J = 8.8 Hz), 7.17 (d, 2 H, J = 9.0 Hz), 7.51 (dd, 1 H, J = 8.6, 2.4 Hz), 8.01 (dd, 1 H, J = 2.4, 0.6 Hz). 13C NMR (100 MHz, CDCl3): δ = 11.3, 17.4, 25.3, 44.3, 50.8, 53.8, 55.4, 111.5, 114.6, 116.9, 119.0, 128.8, 132.0, 132.7, 140.7, 148.6, 160.5, 164.5, 183.1. ESI-MS m/z: 867.3608 (M − Br)+, calculated: 867.3661.
1H NMR (400 MHz, CD3CN): δ = 0.89 (t, 6 H, J = 7.4 Hz), 1.38 (t, 6 H, J = 7.4 Hz), 1.81 (qt, 4 H, J = 7.4, 7.4 Hz), 3.93 (s, 6 H), 4.10–4.30 (m, 8 H), 6.78 (d, 2 H, J = 8.4 Hz), 7.10 (t, 4 H, J = 8.4 Hz), 7.24–7.31 (m, 4 H), 7.52 (dd, 2 H, J = 8.8, 2.6 Hz), 8.01 (d, 2 H, J = 2.0 Hz). 13C NMR (100 MHz, CD3CN): δ = 11.3, 17.3, 25.3, 44.4, 50.9, 53.8, 111.6, 116.5 (d, J = 21.8 Hz), 123.2 (d, J = 3.4 Hz), 129.2, 131.8, 132.7 (d, J = 8.7 Hz), 140.7, 148.6, 163.4 (d, J = 251.0 Hz), 164.6, 183.4. ESI-MS m/z: 875.3123 (M − Br)+, calculated: 875.3159.
1H NMR (400 MHz, CDCl3): δ = 0.91 (t, 6 H, J = 7.4 Hz), 1.43 (t, 6 H, J = 7.4 Hz), 1.79 (qt, 2 H, J = 7.4, 7.4 Hz), 3.93 (s, 6 H), 4.02–4.05 (m, 4 H), 4.15 (qt, 4 H, J = 7.4, 7.4 Hz), 6.79 (dd, 2 H, J = 8.8, 2.6 Hz), 7.10 (t, 1 H, J = 8.4 Hz), 7.12 (t, 1 H, J = 8.4 Hz), 7.39–7.43 (m, 4 H), 7.53 (dd, 2 H, J = 8.8, 2.6 Hz), 8.05 (d, 2 H, J = 2.0 Hz). 13C NMR (100 MHz, CDCl3): δ = 11.3, 17.4, 25.3, 44.6, 50.9, 53.8, 111.6, 117.5 (d, J = 68.3 Hz), 126.8 (d, J = 4.6 Hz), 129.2, 131.1 (d, J = 8.7 Hz), 131.4, 140.7, 148.6, 161.5, 163.9, 164.8, 183.7. ESI-MS m/z: 875.3123 (M − Br)+, calculated: 875.3159.
1H NMR (400 MHz, CDCl3): δ = 0.89 (t, 6 H, J = 7.4 Hz), 1.38 (t, 6 H, J = 7.2 Hz), 1.81 (qt, 4 H, J = 7.4, 7.4 Hz), 3.81 (s, 3 H), 3.93 (s, 3 H), 4.10–4.28 (m, 8 H), 6.77 (dd, 2 H, J = 8.6, 0.6 Hz), 6.90 (d, 4 H, J = 8.8 Hz), 7.17 (d, 4 H, J = 9.0 Hz), 7.51 (dd, 2 H, J = 8.6, 2.4 Hz), 8.01 (dd, 2 H, J = 2.4, 0.6 Hz). 13C NMR (100 MHz, CDCl3): δ = 11.3, 17.4, 25.3, 44.3, 50.8, 53.8, 55.4, 111.5, 114.6, 116.9, 119.0, 128.8, 132.0, 132.7, 140.7, 148.6, 160.5, 164.5, 183.1. ESI-MS m/z: 899.3539 (M − Br)+, calculated: 899.3559.
1H NMR: (400 MHz, CDCl3): δ = 0.89 (t, 6 H, J = 8.0 Hz), 1.35 (t, 6 H, J = 8.0 Hz), 1.81–1.89 (m, 4 H), 3.80 (s, 6 H), 3.91 (s, 6 H), 3.99–4.08 (m, 4 H), 4.13–4.19 (m, 4 H), 6.75 (d, 2 H, J = 8.4 Hz), 6.93–6.96 (m, 4 H), 7.10 (dd, 2 H, J = 7.7, 1.7 Hz), 7.39 (dt, 2 H, J = 8.4, 1.4 Hz), 7.51 (dd, 2 H, J = 8.5, 2.5 Hz), 7.99 (d, 2 H, J = 1.9 Hz). 13C NMR (100 MHz, CDCl3): δ = 11.3, 17.2, 25.4, 44.6, 50.8, 53.8, 55.6, 111.3 (twice), 115.8, 117.2, 121.1, 129.3, 132.0, 132.9, 140.7, 148.3, 158.2, 164.6, 183.2. ESI-MS m/z: 899.3539 (M − Br)+, calculated: 899.3559.
The proliferation and the metabolic activity in the absence of the compounds were set at 100%.
CDCl3 | Deuterated chloroform |
CD3CN | Deuterated acetonitrile |
CHCl3 | Chloroform |
DCM | Dichloromethane |
DTNB | 5,5′-Dithiobis-(2-nitrobenzoic acid) |
eq. | Equivalents |
EtOAc | Ethyl acetate |
ESI-MS | Electrospray ionisation mass spectrometry |
FBS | Fetal bovine serum |
HPLC | High performance liquid chromatography |
mROS | Mitochondrial ROS |
MeOH | Methanol |
MTT | 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
NHC | N-Heterocyclic carbene |
NMR | Nuclear magnetic resonance |
o/n | Overnight |
ORTEP | Oak ridge thermal-ellipsoid plot |
ROS | Reactive oxygen species |
RPMI | Roswell park memorial institute |
rt | Room temperature |
SAR | Structure–activity relationship |
STI | Imatinib mesylate |
TFA | Trifluoroacetic acid |
TNB | 5-Thio-2-nitrobenzoic acid |
Trx | Thioredoxin |
TrxR | Thioredoxin reductase |
Footnotes |
† Electronic supplementary information (ESI) available: 1H NMR, 13C NMR and ESI-MS spectra of 2a–f, the HPLC chromatograms of 2a–f, and the anti-metabolic activity of 2a–f against LAMA-84 (STI-sensitive and -resistant) cells, HL-60 cells and non-cancerous SV-80 cells. CCDC 1923123. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0dt03902k |
‡ These authors contributed equally to this publication. |
This journal is © The Royal Society of Chemistry 2021 |